Notably, the plasma level of osteopontin is associated with diabetic nephropathy progression in both type 1 and type 2 diabetes [35, 36], and the genetic ablation of osteopontin attenuated diabetic glomerulopathy in the mouse models of type 1 and type 2 diabetes [37]. This evidence concerns the gene SPP1 and diabetic kidney disease.